- Roche (OTCQX:RHHBY) will collaborate with Boston, MA-based Atea Pharmaceuticals to develop an oral small molecule direct-acting antiviral to treat COVID-19 infection.
- The candidate, dubbed AT-527, is currently in a Phase 2 study in hospitalized patients with moderate symptoms. A Phase 3 trial in non-hospitalized patients should launch next quarter. It may also be explored for post-exposure prophylaxis.
- AT-527, a purine nucleotide prodrug, works by blocking a key enzyme, RNA polymerase, that plays an essential role in viral replication. It is also being developed for the treatment of hepatitis C virus (HCV) infection.
- https://seekingalpha.com/news/3624692-roche-teams-up-atea-pharma-to-develop-oral-covidminus-19-drug
Thursday, October 22, 2020
Roche teams up with Atea Pharma to develop oral COVID-19 drug
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.